The acquired osimertinib resistance is highly variable, covering EGFR-dependent as well as EGFR-independent mechanisms, as a result of the high degree of tumor heterogeneity and adaptive cellular signaling pathways in NSCLC. Here, EGFR is linked to neoplasm.